PharmaNet has reported second quarter results that place it back in
the red after it had only just clawed its way back into the black
in the first quarter, following a string of quarterly losses.
MDS Pharma Services has announced it is expanding its development
and regulatory services (DRS) business in Europe while its
bioanalytical operations are still struggling.
Contract manufacturer Granules India is moving towards vertical
integration, with a new tabletting facility scheduled to come
onstream this August at the company's Gagillapur site near
Hyderabad in India.
Charles River has posted first quarter results that beat analysts
expectations after seeing renewed growth in its research models and
services segment.
Solid oral dose product specialist Almac Pharma has announced it
has expanded its formulation facilities located at its UK
headquarters to provide a wider range of services to pharma and
biotech companies.
India's Dishman Pharmaceuticals & Chemicals is planning to snap
up biotech and nanotech contract research organisation (CRO)
companies in Europe and in the US within drug conjugates to expand
their biologics capability.
According to a new report, CRO's are primarily selected on their
scientific expertise and the cost/value ratio as pharmaceutical and
biotech companies look to speed up the research and development
process whilst adhering to stricter...
PPD managed a net revenue of $313.1m (€250m) for the third quarter
of 2006, an increase of 14.6 per cent over net revenue of $273.3m
for the third quarter of 2005. This has been buoyed on by the
strong performance by the company's...
Ferro Pfanstiehl Laboratories has commissioned a new validated
current good manufacturing practice (cGMP) supercritical
fluid-based particle engineering pilot facility, offering sizing,
purification and formulation services to its...
Canadian contract manufacturer Patheon has teamed up with specialty
pharmaceutical firm Depomed to offer its clients a controlled
release formulation which can grant their drugs increased
bioavailability and less frequent dosing.
Drug manufacturers are increasingly turning to specialised
providers of analytical services for the solid state
characterisation of their formulations, seeking answers to
processing issues, drug delivery challenges and even protecting...
More and more drugmakers are turning to health care companies not
just for their drug delivery technologies but also for their
regulatory and manufacturing expertise, asking them to take their
product from early stages all the way...
Are big pharma companies uninterested in supporting novel
formulations, preferring to stick to low-risk drug delivery
systems, or are they resourceful innovators that bring new
technologies to the market? Two pharma grandees holding...
SR Pharma has recruited Genzyme, BioSpring and OctoPlus to
formulate and manufacture its lead RNAi therapeutic product Atu027
to good manufacturing practice (GMP) standards, as its liposomal
drug delivry system moves forward.
Drug delivery firm Egalet has asked SP Medical, a manufacturer of
moulded plastics and coatings, to make sufficient clinical grade
quantities of its therapeutics using injection moulding, which
allows for greater uniformity and reproducibility...
The Tampa-based formulation development laboratory of MDS Pharma
Services has split from its parent company and formed a new firm
with the technology to get active pharmaceutical ingredients (APIs)
directly into capsules.
India's Dishman Pharmaceuticals & Chemicals has snapped up the
Swiss-based pharmaceutical services business, Carbogen and Amcis,
of financially-troubled US chemical firm Solutia for the sum of
$74.5m (€58m).
The boom in advanced drug delivery devices is creating demand for
specialist manufacturers that can rise to the challenge of making
these complicated devices, although such companies are currently
thin on the ground.
Switzerland's Lonza, one of the leading contract manufacturers of
active pharmaceutical ingredients, has forged a collaboration with
RNA-TEC of Belgium to provide broad-ranging contract production of
oligonucleotides, a new class...
Pliva has continued its rapid expansion with the opening of a new
R&D facility in the USA that will carry out formulation work on
generic pharmaceuticals.
Speciality chemicals company International Specialty Products (ISP)
continues its quest to expand the company's presence in the growing
personal care market segment with the news this week that it has
collaborated with biotech...
UK-based vaccine maker PowderJect is now said to be in the latter
stages of takeover negotiations, with the interested party widely
tipped to be the USA's Chiron, rumoured to be proferring a bid
valuing the company at around...
Spotlight on the home of the celebrated pork pie in England, with
the annoucement this week that Melton Mowbray-based Bridgehead
Technologies and Pharmalicensing - two biopharmaceutical business
development companies - are to merge.
US biopharmaceutical company Scolr, latterly known as Nutraceutix,
is to ship the first order for its patented controlled delivery
product Glucosamine/Chondroitin to Europe.
UK developer of medical diagnostics devices Osmetech continued the
strategy to build on its healthcare diagnostics business with the
acquisition this week of the Atlanta-based 'OPTI' product line of
blood gas analysers owned...
Franco-German drugmaker Aventis and Germany's Bayer have agreed not
to pursue their plans to create a joint venture in the field of
biological products.
Crosslinking is a natural phenomenon occurring in gelatin that negatively impacts soft capsules, reducing their stability and prolonging their dissolution...
New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...
Invivo: Many orally dosed APIs are bioavailable only when formulated as an enteric dosage form to protect them from the harsh environment of the stomach....
